Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Assets Average (2022 - 2025)

Historic Assets Average for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $245.3 million.

  • Phathom Pharmaceuticals' Assets Average fell 3056.41% to $245.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $245.3 million, marking a year-over-year decrease of 3056.41%. This contributed to the annual value of $396.1 million for FY2024, which is 3689.75% up from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Assets Average stood at $245.3 million for Q3 2025, which was down 3056.41% from $272.2 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Assets Average high stood at $385.2 million for Q1 2024, and its period low was $154.4 million during Q1 2023.
  • Its 4-year average for Assets Average is $272.9 million, with a median of $261.6 million in 2023.
  • As far as peak fluctuations go, Phathom Pharmaceuticals' Assets Average skyrocketed by 14944.66% in 2024, and later tumbled by 3056.41% in 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' Assets Average (Quarter) stood at $183.4 million in 2022, then surged by 77.46% to $325.4 million in 2023, then increased by 17.6% to $382.7 million in 2024, then plummeted by 35.91% to $245.3 million in 2025.
  • Its Assets Average was $245.3 million in Q3 2025, compared to $272.2 million in Q2 2025 and $336.3 million in Q1 2025.